Trial · NCT01435993
Multiple Doses of Anti-NOGO A in Relapsing Forms of Multiple Sclerosis
NCT01435993, Phase 1, Terminated, GlaxoSmithKline
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Multiple Doses of Anti-NOGO A in Relapsing Forms of Multiple Sclerosis. Trials, record NCT01435993. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01435993
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Multiple Doses of Anti-NOGO A in Relapsing Forms of Multiple Sclerosis
- NCT number
- NCT01435993
- Status
- Terminated
- Phases
- Phase 1
- Enrollment
- 3 participants, actual
- Lead sponsor
- GlaxoSmithKline
- Conditions
- Multiple Sclerosis, Relapsing-Remitting
- Interventions
- GSK1223249, Saline placebo
- First posted
- 2011-09-19
- Last updated
- 2020-11-24
- Other registries' IDs
- eudract:2010-022664-12
Source ClinicalTrials.gov
Registered outcomes4
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Safety | every 2-4 weeks over 7 months | • Changes in vital signs, ECG monitoring, blood chemistry, haematology, urinalysis, monitoring of AEs and MS relapses (number, incidence, severity) |
| Secondary | Cmax values and AUC(0-∞) | Pre-dose; 1hr; 6hr; 12hr; 48hr; Day7; Day13; Follow-up | Profile of Pharamcokinetics |
| Secondary | Immunogenicity of GSK1223249 in MS patients | Predose; Day 85; Day169; Day197 | • Presence of antibodies to GSK1223249 to be assessed in serum samples using validated ECL assays. |
| Secondary | Pharmacokinetics of GSK1223249 in cerebro-spinal fluid (CSF) in MS patients | Day7; or Day 29; or Day 35; or Day 85 | Measurement of GSK1223249 in CSF |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT01435993
GET https://conductscience.org/api/trials/v1/NCT01435993/registered